The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients
Phase 4
- Conditions
- Pertussis
- Registration Number
- NCT00336115
- Lead Sponsor
- Queen Elizabeth II Health Sciences Centre
- Brief Summary
The purpose of this study is to determine if pertussis (whooping cough) vaccine is safe and produces an appropriate immune response against pertussis in blood and marrow transplant patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
- Aged 18-64
- BMT at the QEII Health Sciences Centre
- BMT within last 12 months
- Able to read and write English language
- Able to give consent
Exclusion Criteria
- Active infection
- Active GVHD
- Recent IVIG
- Allergy to components of vaccine
- Diphtheria or tetanus vaccination within 18 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Safety of the vaccine 28 days post-dose
- Secondary Outcome Measures
Name Time Method Immunogenicity of vaccine 60 days post-dose